Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

Improved biomarkers are required to guide the optimal use of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We hypothesized that minimal residual disease (MRD) identified using immunoglobulin high-throughput sequencing in...

Descripción completa

Detalles Bibliográficos
Autores principales: Merryman, Reid W., Redd, Robert A., Taranto, Eleanor, Ahmed, Gulrayz, Jeter, Erin, McHugh, Kristin M., Brown, Jennifer R., Crombie, Jennifer L., Davids, Matthew S., Fisher, David C., Freedman, Arnold S., Jacobsen, Eric, Jacobson, Caron A., Kim, Austin I., LaCasce, Ann S., Ng, Samuel Y., Odejide, Oreofe O., Parry, Erin M., Jacene, Heather, Park, Hyesun, Dahi, Parastoo B., Nieto, Yago, Joyce, Robin M., Chen, Yi-Bin, Shipp, Margaret A., Herrera, Alex F., Armand, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468363/
https://www.ncbi.nlm.nih.gov/pubmed/36399518
http://dx.doi.org/10.1182/bloodadvances.2022007706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468363/
https://www.ncbi.nlm.nih.gov/pubmed/36399518
http://dx.doi.org/10.1182/bloodadvances.2022007706

Ejemplares similares